Literature DB >> 33651969

Hypouricaemic and nephroprotective effects of Poria cocos in hyperuricemic mice by up-regulating ATP-binding cassette super-family G member 2.

Danling Liang1,2,3,4, Tianqiao Yong1,2, Xue Diao1,2, Shaodan Chen1,2, Diling Chen1,2, Chun Xiao1, Dan Zuo5, Yizhen Xie1,2, Xinxin Zhou3, Huiping Hu1,2.   

Abstract

CONTEXT: Poria coco F.A.Wolf (Polyporaceae) dispels dampness and promotes diuresis implying hypouricaemic action.
OBJECTIVE: To examine hypouricaemic action of Poria coco.
MATERIALS AND METHODS: Ethanol extract (PCE) was prepared by extracting the sclerotium of P. cocos with ethanol, and the water extract (PCW) was produced by bathing the remains with water. PCE and PCW (50, 100 and 200 mg/kg, respectively) were orally administered to hyperuricemic Kunming mice (n = 8) to examine its hypouricaemic effect. Also, molecular docking was performed.
RESULTS: P. cocos showed excellent hypouricaemic action, decreasing the serum uric acid of hyperuricaemia (HUA) control (526 ± 112 μmol/L) to 178 ± 53, 153 ± 57 and 151 ± 62 μmol/L (p < 0.01) by PCE and 69 ± 23, 63 ± 15 and 62 ± 20 μmol/L (p < 0.01) by PCW, respectively. According to SCrs, BUNs and H&E staining, PCE and PCW partially attenuated renal dysfunction caused by HUA. They presented no negative effects on ALT, AST and ALP activities. They elevated ABCG2 (ATP-binding cassette super-family G member 2) mRNA and protein expression in comparison to HUA control. In molecular docking, compound 267, 277, 13824, 15730 and 5759 were predicted as the top bioactives of P. cocos against HUA, which even presented better scores than the positive compound, oestrone 3-sulfate. DISCUSSION AND
CONCLUSIONS: This paper demonstrated the hypouricaemic and nephroprotective effects of P. cocos in hyperuricemic mice by up-regulating ABCG2. These results may be useful for the development of a hypouricaemic agent.

Entities:  

Keywords:  Uric acid; bioactives; higher fugal; molecular docking; transportation

Mesh:

Substances:

Year:  2021        PMID: 33651969      PMCID: PMC7928048          DOI: 10.1080/13880209.2021.1885450

Source DB:  PubMed          Journal:  Pharm Biol        ISSN: 1388-0209            Impact factor:   3.503


  34 in total

1.  Inhibition of xanthine oxidase by some Chinese medicinal plants used to treat gout.

Authors:  L D Kong; Y Cai; W W Huang; C H Cheng; R X Tan
Journal:  J Ethnopharmacol       Date:  2000-11       Impact factor: 4.360

Review 2.  Global epidemiology of gout: prevalence, incidence and risk factors.

Authors:  Chang-Fu Kuo; Matthew J Grainge; Weiya Zhang; Michael Doherty
Journal:  Nat Rev Rheumatol       Date:  2015-07-07       Impact factor: 20.543

3.  TCMAnalyzer: A Chemo- and Bioinformatics Web Service for Analyzing Traditional Chinese Medicine.

Authors:  Zhihong Liu; Jiewen Du; Xin Yan; Jiali Zhong; Lu Cui; Jinyuan Lin; Lizhu Zeng; Peng Ding; Pin Chen; Xinxin Zhou; Huihao Zhou; Qiong Gu; Jun Xu
Journal:  J Chem Inf Model       Date:  2018-03-01       Impact factor: 4.956

4.  Flexible CDOCKER: Development and application of a pseudo-explicit structure-based docking method within CHARMM.

Authors:  Jessica K Gagnon; Sean M Law; Charles L Brooks
Journal:  J Comput Chem       Date:  2015-12-21       Impact factor: 3.376

5.  Contemporary Prevalence of Gout and Hyperuricemia in the United States and Decadal Trends: The National Health and Nutrition Examination Survey, 2007-2016.

Authors:  Michael Chen-Xu; Chio Yokose; Sharan K Rai; Michael H Pillinger; Hyon K Choi
Journal:  Arthritis Rheumatol       Date:  2019-04-15       Impact factor: 10.995

6.  Wuling San protects kidney dysfunction by inhibiting renal TLR4/MyD88 signaling and NLRP3 inflammasome activation in high fructose-induced hyperuricemic mice.

Authors:  Ying Yang; Dong-Mei Zhang; Jia-Hui Liu; Lin-Shui Hu; Qiao-Chu Xue; Xiao-Qin Ding; Ling-Dong Kong
Journal:  J Ethnopharmacol       Date:  2015-04-23       Impact factor: 4.360

Review 7.  A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients?

Authors:  Ming-Han H Lee; Garry G Graham; Kenneth M Williams; Richard O Day
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

8.  Anti-Hyperglycemic Properties of Crude Extract and Triterpenes from Poria cocos.

Authors:  Tzu-Hsuan Li; Chia-Chung Hou; Cicero Lee-Tian Chang; Wen-Chin Yang
Journal:  Evid Based Complement Alternat Med       Date:  2010-09-16       Impact factor: 2.629

9.  ABCG2 dysfunction causes hyperuricemia due to both renal urate underexcretion and renal urate overload.

Authors:  Hirotaka Matsuo; Akiyoshi Nakayama; Masayuki Sakiyama; Toshinori Chiba; Seiko Shimizu; Yusuke Kawamura; Hiroshi Nakashima; Takahiro Nakamura; Yuzo Takada; Yuji Oikawa; Tappei Takada; Hirofumi Nakaoka; Junko Abe; Hiroki Inoue; Kenji Wakai; Sayo Kawai; Yin Guang; Hiroko Nakagawa; Toshimitsu Ito; Kazuki Niwa; Ken Yamamoto; Yutaka Sakurai; Hiroshi Suzuki; Tatsuo Hosoya; Kimiyoshi Ichida; Toru Shimizu; Nariyoshi Shinomiya
Journal:  Sci Rep       Date:  2014-01-20       Impact factor: 4.379

10.  Efficacy and safety of Lianhuaqingwen capsules, a repurposed Chinese herb, in patients with coronavirus disease 2019: A multicenter, prospective, randomized controlled trial.

Authors:  Ke Hu; Wei-Jie Guan; Ying Bi; Wei Zhang; Lanjuan Li; Boli Zhang; Qingquan Liu; Yuanlin Song; Xingwang Li; Zhongping Duan; Qingshan Zheng; Zifeng Yang; Jingyi Liang; Mingfeng Han; Lianguo Ruan; Chaomin Wu; Yunting Zhang; Zhen-Hua Jia; Nan-Shan Zhong
Journal:  Phytomedicine       Date:  2020-05-16       Impact factor: 5.340

View more
  2 in total

Review 1.  Traditional Chinese herbs and natural products in hyperuricemia-induced chronic kidney disease.

Authors:  Letian Yang; Bo Wang; Liang Ma; Ping Fu
Journal:  Front Pharmacol       Date:  2022-08-09       Impact factor: 5.988

2.  Three main metabolites from Wolfiporia cocos (F. A. Wolf) Ryvarden & Gilb regulate the gut microbiota in mice: A comparative study using microbiome-metabolomics.

Authors:  Yong Lai; Hailun Yu; Huiling Deng; Qi Fang; Hui Lei; Li Liu; Nannan Wu; Xiurong Guo; Can Song
Journal:  Front Pharmacol       Date:  2022-08-03       Impact factor: 5.988

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.